PING AN BIOMEDICAL CO LTD (PASW) Stock Fundamental Analysis

NASDAQ:PASW • KYG5880S1057

0.167 USD
+0 (+0.24%)
Last: Feb 23, 2026, 02:40 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to PASW. PASW was compared to 23 industry peers in the Distributors industry. Both the profitability and financial health of PASW have multiple concerns. PASW does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PASW has reported negative net income.
  • In the past year PASW had a positive cash flow from operations.
PASW Yearly Net Income VS EBIT VS OCF VS FCFPASW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 5M -5M 10M 15M 20M

1.2 Ratios

  • With a Return On Assets value of -11.35%, PASW is not doing good in the industry: 69.57% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -11.35%
ROE N/A
ROIC N/A
ROA(3y)1.77%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PASW Yearly ROA, ROE, ROICPASW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 100 150

1.3 Margins

  • PASW has a Gross Margin of 4.46%. This is in the lower half of the industry: PASW underperforms 73.91% of its industry peers.
  • PASW does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PASW Yearly Profit, Operating, Gross MarginsPASW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 2 4 6 8 10

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • PASW does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PASW has about the same amount of shares outstanding.
  • PASW has a better debt/assets ratio than last year.
PASW Yearly Shares OutstandingPASW Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
PASW Yearly Total Debt VS Total AssetsPASW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of 1.53, we must say that PASW is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.53, PASW is doing worse than 69.57% of the companies in the same industry.
  • The Debt to FCF ratio of PASW is 0.91, which is an excellent value as it means it would take PASW, only 0.91 years of fcf income to pay off all of its debts.
  • PASW has a Debt to FCF ratio of 0.91. This is amongst the best in the industry. PASW outperforms 82.61% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0.91
Altman-Z 1.53
ROIC/WACCN/A
WACC3.95%
PASW Yearly LT Debt VS Equity VS FCFPASW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

  • PASW has a Current Ratio of 0.77. This is a bad value and indicates that PASW is not financially healthy enough and could expect problems in meeting its short term obligations.
  • PASW has a Current ratio of 0.77. This is amonst the worse of the industry: PASW underperforms 82.61% of its industry peers.
  • PASW has a Quick Ratio of 0.77. This is a bad value and indicates that PASW is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.76, PASW perfoms like the industry average, outperforming 43.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.76
PASW Yearly Current Assets VS Current LiabilitesPASW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • PASW shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -707.05%.
  • Looking at the last year, PASW shows a very negative growth in Revenue. The Revenue has decreased by -17.49% in the last year.
EPS 1Y (TTM)-707.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2127.59%
Revenue 1Y (TTM)-17.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-60.13%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PASW Yearly Revenue VS EstimatesPASW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • PASW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PASW Price Earnings VS Forward Price EarningsPASW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PASW indicates a rather cheap valuation: PASW is cheaper than 95.65% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 2.57
EV/EBITDA N/A
PASW Per share dataPASW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PASW does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PING AN BIOMEDICAL CO LTD

NASDAQ:PASW (2/23/2026, 2:40:42 PM)

0.167

+0 (+0.24%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustryDistributors
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.14%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.10M
Revenue(TTM)105.85M
Net Income(TTM)-5.52M
AnalystsN/A
Price TargetN/A
Short Float %0.88%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.27
P/FCF 2.57
P/OCF 2.57
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.07
FCFY38.96%
OCF(TTM)0.07
OCFY38.96%
SpS0.62
BVpS-0.07
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.46%
FCFM 10.43%
ROA(3y)1.77%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover2.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0.91
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.76
Altman-Z 1.53
F-Score4
WACC3.95%
ROIC/WACCN/A
Cap/Depr(3y)33.6%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-707.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2127.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-60.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-311.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y340.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y340.52%
OCF growth 3YN/A
OCF growth 5YN/A

PING AN BIOMEDICAL CO LTD / PASW FAQ

Can you provide the ChartMill fundamental rating for PING AN BIOMEDICAL CO LTD?

ChartMill assigns a fundamental rating of 1 / 10 to PASW.


What is the valuation status for PASW stock?

ChartMill assigns a valuation rating of 2 / 10 to PING AN BIOMEDICAL CO LTD (PASW). This can be considered as Overvalued.


What is the profitability of PASW stock?

PING AN BIOMEDICAL CO LTD (PASW) has a profitability rating of 0 / 10.